Aileron Therapeutics (ALRN)
(Delayed Data from NSDQ)
$2.45 USD
+0.13 (5.60%)
Updated Aug 26, 2024 03:59 PM ET
After-Market: $2.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Aileron Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 28 | 27 | 21 | 30 |
Income After Depreciation & Amortization | -16 | -28 | -27 | -21 | -30 |
Non-Operating Income | 1 | 0 | 0 | -1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -16 | -27 | -26 | -21 | -29 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -16 | -27 | -26 | -21 | -29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -16 | -27 | -26 | -21 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -28 | -26 | -20 | -30 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -16 | -28 | -27 | -21 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.60 | 4.54 | 4.44 | 1.74 | 1.23 |
Diluted EPS Before Non-Recurring Items | -3.20 | -6.02 | -5.80 | -12.20 | -24.00 |
Diluted Net EPS (GAAP) | -3.42 | -6.02 | -5.80 | -12.20 | -24.00 |
Fiscal Year end for Aileron Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 9.04 | 7.20 | 7.29 | 1.98 | 2.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | -9.04 | -7.20 | -7.29 | -1.98 | -2.00 |
Non-Operating Income | 0.10 | 0.09 | 0.27 | 0.16 | 0.21 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -8.94 | -7.11 | -7.34 | -1.83 | -1.79 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.94 | -7.11 | -7.34 | -1.83 | -1.79 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.94 | -7.11 | -7.34 | -1.83 | -1.79 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 19.91 | 8.30 | 4.77 | 4.54 | 4.54 |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.86 | -1.54 | -0.40 | -0.39 |
Diluted Net EPS (GAAP) | -0.45 | -0.86 | -1.58 | -0.40 | -0.39 |